Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 28Multiple Myeloma 26Lymphoma 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Myelodysplastic Syndromes 19Lymphoma, Follicular 18Recurrence 16Lymphoma, B-Cell 16Leukemia 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Neuroblastoma 10Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 10Sarcoma 8Melanoma 8Medulloblastoma 8Rhabdomyosarcoma 7Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6

Interventions

sargramostim 1ribociclib 1palbociclib 1abemaciclib 1Letrozole 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Unilateral Breast Neoplasms × Cyclophosphamide × Clear all
NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡